<DOC>
	<DOC>NCT00549055</DOC>
	<brief_summary>To assess effectiveness of Macugen for treatment of neovascular age-related macular degeneration by measuring the evolution of visual acuity. Treatment duration, frequency of administration and combination with other treatments will also be evaluated.</brief_summary>
	<brief_title>A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Patients diagnosed with subfoveal neovascular (wet) agerelated macular degeneration Patients having received at least 1 Macugen injection Treatment naive patients, or patients having received conventional therapy Patients having signed and dated informed consent. Patients participating in another clinical study with Macugen.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Macugen Age-related macular degeneration (AMD) Observational study</keyword>
</DOC>